Secluded for three days at the border of an expansive wilderness in Eastern Australia, an international group of leading scientists appraised where research on Alzheimer's and aging stands at this juncture, and formulated recommendations for how to move forward. The researchers discussed what the field at large can learn from the disheartening failure of recent drug trials. The scientists identified a set of priority research topics and articulated for each of them how model systems and human research could intersect to ensure insights relevant to the human condition. Throughout, the scientists paid heed to bridging basic, translational, and clinical research. They argued forcefully for biomarker-driven preclinical trials in selected high-risk populations and for more research funding.